Upon getting elected, Trump made a top drug-company executive head of Health and Human Services, and the campaign promise vanished. But we can now update his figure on savings to at least $450 billion over 10 years, based on Congressional Budget Office numbers.
Most of those savings wouldn’t leave the Medicare program but, as the budget plan says, go to providing dental, hearing and vision coverage. And beneficiaries would enjoy a $14 billion cut in their Part D premiums by 2029, according to the Henry J. Kaiser Family Foundation.
Then there are the taxpayers. General revenues — that is, federal income taxes — cover 71 percent of the costs of Medicare Part D, and states another 12 percent.
This proposal hardly starves the pharmaceutical companies of revenues. It would cap the prices charged Medicare at 120 percent of those paid in Australia, Canada, France, Germany, Japan and the United Kingdom.
In other words, we could still be paying more than these other rich countries. The difference is that drugmakers could no longer gouge Americans with impunity.
The proposed Medicare cap would have reduced U.S. spending on insulin and 50 top brand-name drugs by 52 percent during 2020 — a savings of $83.5 billion, according to a RAND Corporation report. (The Veterans Administration has long negotiated prices and pays 54 percent less for drugs than does Medicare.)
PhRMA’s public relations department recently wrote that efforts to stop drugmakers from charging the federal health insurance program for the elderly whatever they want “should enrage every senior who relies on Medicare for their life-saving medicines.”
Actually, they’re not enraged. An AARP survey finds that 87 percent of Americans 50 and older support letting Medicare negotiate drug prices. And nearly 90 percent of the general public wants it, according to a Kaiser Family Foundation poll.
One PhRMA ad falsely claims that politicians will “decide which medicines you can and can’t get.” The budget bill does no such thing. It would not require a prescription drug formulary. Insurers offering Medicare drug plans would still decide what drugs to cover. The negotiations would apply to only a few drugs that account for the highest spending and that lack generic competitors.
Lawmakers intent on protecting the drug-pricing racket include some Democrats. What most have in common with like-minded Republicans is open palms at the bottom of Big Pharma’s money chute.
At some point, Americans will stop playing the world’s suckers. Letting Medicare negotiate drug prices would be a fine place to start recovering our self-respect.